Allergan PLC. (AGN) PT Set at $231.00 by Cantor Fitzgerald
Allergan PLC. (NYSE:AGN) has been given a $231.00 price objective by analysts at Cantor Fitzgerald in a note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 13.19% from the company’s previous close.
A number of other brokerages also recently weighed in on AGN. Mizuho restated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company boosted their target price on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $271.64.
Shares of Allergan PLC. (NYSE AGN) traded down 1.22% on Thursday, hitting $204.08. 1,986,247 shares of the stock traded hands. The firm’s 50 day moving average is $216.96 and its 200 day moving average is $232.50. The firm has a market capitalization of $68.23 billion, a PE ratio of 6.22 and a beta of 1.15. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 earnings per share. On average, analysts expect that Allergan PLC. will post $16.21 EPS for the current fiscal year.
Allergan PLC. announced that its Board of Directors has initiated a share buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
Several institutional investors have recently made changes to their positions in the company. Hudock Capital Group LLC lifted its position in Allergan PLC. by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after purchasing an additional 2 shares during the period. GWM Advisors LLC lifted its position in Allergan PLC. by 0.4% during the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after purchasing an additional 5 shares during the period. Burns J W & Co. Inc. NY lifted its position in Allergan PLC. by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the period. Pacific Center for Financial Services lifted its position in Allergan PLC. by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC lifted its position in Allergan PLC. by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the period. 82.04% of the stock is owned by institutional investors.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.